Michael Jordan gives $10M for North Carolina health cli accesswdun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from accesswdun.com Daily Mail and Mail on Sunday newspapers.
After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration.
The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung cancer (ES-SCLC).
“Cosela will help change the chemotherapy experience for people who are battling ES-SCLC,” said Jack Bailey, the company’s chief executive officer. “G1 is proud to deliver Cosela to patients and their families as the first and only therapy to help protect against chemotherapy-induced myelosuppression.”
Four potential COVID-19 therapeutics enter Phase 2/3 testing
Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of promising COVID-19 treatments and vaccines. The new agents entering the randomized, placebo-controlled study are part of ACTIV-2, an adaptive trial designed to test investigational agents in non-hospitalized adult volunteers experiencing mild to moderate COVID-19 symptoms. ACTIV-2 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, and is led by the NIAID-funded AIDS Clinical Trials Group (ACTG).
February 15, 2021 By Waterways Journal
Jeremy Dyer.
Jeremy Dyer has joined the Towing Vessel Inspection Bureau as operations manager; he will be the primary staff resource for the TPO customer base on the Lower Mississippi River, Gulf Coast and East Coast, and will work alongside Caleb King, focusing on the coordination of audits and surveys while working to support TPO customers with CG-835V/Marine Casualty concerns and related TPO activities.
Dyer has more than 21 years of marine-industry experience in both the private sector and the U.S. Coast Guard. He previously worked as a Subchapter M lead auditor and consultant with Halter Consulting Inc. Prior to that, he was the director of compliance for the River Division of Marquette Transportation Company LLC. There, his responsibilities included Subchapter M implementation; development, implementation and maintenance of an ISM compliant safety management system; an
Family Life Project identifies a wide array of risks from infancy through teen years
Image: Adobe Stock
January 28, 2021
UNIVERSITY PARK, Pa. When parents think of baby-proofing, they may think of baby gates and outlet covers, but there might be something less obvious to consider: whether previous occupants of their home were smokers. According to a National Institutes of Health-funded study by researchers at Penn State and the University of North Carolina at Chapel Hill (UNC), babies can be exposed to nicotine left behind in the home.
Infants and toddlers may be at higher risk of exposure than older children. “Babies spend a lot of time on the ground, and tend to put everything into their mouths, so they may ingest nicotine from surfaces such as furniture and floors where smoke has settled,” explained the study’s principal investigator, Lisa Gatzke-Kopp, professor of human development and family studies at Penn State. “We found that some babies had exposure levels as h